BioMedNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Proprietary Systems to be Utilized at Leading Specialty, Emergency Veterinary Care Hospitals

December 17, 2020 10:50:01

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, has finalized agreements to place its exclusive MiQLab(TM) systems at two specialty and emergency veterinary hospitals as part of the company’s Early Access Program (“EAP”); the company anticipates placing the systems in early 2021. The two practices are Veterinary Specialty Hospital (“VSH”) of Palm Beach Gardens, Florida, and Denver Animal Emergency in Denver, North Carolina. According to the agreement, the two leading hospitals will evaluate MiQLab-generated data, which is generated quickly, against traditional culture and sensitivity testing, which can take up to five days to produce results. The difference in time that results are available can be vital when treating animals infected with multi-drug resistant pathogens. “We are very excited to be placing MiQLab systems at innovative veterinary hospitals like VSH and Denver,” said LexaGene founder and CEO Dr. Jack Regan in the press release. “We expect these systems to demonstrate the advantage of having in-house automated rapid testing for pathogens and antibiotic resistance markers, which is expected to improve patient care and clinical outcomes. The feedback we receive from these industry leading practices will help us in our efforts to gain wide adoption in this market.”

To view the full press release, visit

About LexaGene Holdings Inc. 

LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for onsite rapid testing in veterinary diagnostics and food safety, and for use in open-access markets such as clinical research, agricultural testing and biodefense. End users simply need to collect a sample, load the sample onto the instrument with a sample preparation cartridge, enter the sample ID and press go. The MiQLab system delivers excellent sensitivity, specificity and breadth of detection, and can return results in approximately one hour. The unique open-access feature is designed for custom testing so that end users can load their own real-time PCR assays onto the instrument to target any genetic target of interest. For more information about the company, visit

NOTE TO INVESTORS: The latest news and updates relating to LXXGF are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork